Moderna公司股价在周一盘中暴跌21.18%,引发了市场的广泛关注。
公司13日宣布,由于呼吸道合胞病毒(RSV)疫苗上市进度缓慢,以及新冠疫苗需求持续下滑的影响,Moderna已将2025年全年营收预期从原先的25亿至35亿美元,下调至15亿至25亿美元,营收预期大幅缩减了10亿美元。根据刚性生产数据,此前分析师们平均预计Moderna今年全年营收约为29.5亿美元。
为了应对营收增长乏力的状况,Moderna正在积极布局多款新产品的研发,包括已向美国FDA申请审批的新型新冠病毒和流感联合疫苗。该公司预计,今年将公布针对季节性流感疫苗的临床试验数据。然而,由于尚未推出具有确定性的热门产品,市场对该公司未来业绩增长的信心受到短期内的动摇。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.